Market Overview - On January 21, Hong Kong stocks experienced a slight adjustment in the morning but rebounded in the afternoon, with the Hang Seng Index rising by 97 points (0.4%) to close at 26,857 points[1] - The Hang Seng Tech Index increased by 62 points (1.1%), closing at 5,746 points, with total market turnover reaching HKD 250.5 billion[1] - Southbound capital inflow expanded to HKD 13.89 billion[1] Sector Performance - The semiconductor sector remained strong, driven by Micron's announcement of a potential memory shortage lasting until 2028, with Hua Hong Semiconductor and SMIC rising by 4%-6%[1] - TCL Electronics surged by 14.8% after announcing a joint venture with Sony, holding a 51% stake[1] - Skyworth Group's stock jumped by 37.5% following its announcement of a spin-off and share buyback[1] Geopolitical Impact - Gold stocks generally rose due to heightened geopolitical tensions, with Lingbao Gold and Zhaojin Mining increasing by 5%-8%[1] - The report suggests a short-term focus on strong sectors such as semiconductors and gold[1] U.S. Market Reaction - In the U.S., the Dow Jones Index rebounded by 588 points (1.5%) to 49,077 points, while the Nasdaq and S&P 500 indices rose by 270 points (1.2%) and 78 points respectively[2] - Gold prices remained strong, peaking at USD 4,888.4 per ounce[2] Macroeconomic Policy - The National Development and Reform Commission outlined policy directions for 2026, focusing on strengthening domestic circulation and expanding domestic demand strategies[3] Automotive Sector - China National Heavy Duty Truck Group saw a 7.5% increase in stock price after a major shareholder reduced their stake by 2%[4] - The company is expected to maintain strong export growth and a high dividend yield of approximately 7%[4] Energy and Utilities - Defensive sectors like environmental protection and gas utilities received support amid rising geopolitical risks, with stocks like Hong Kong and China Gas and CLP Holdings rising by 1.1%-3.2%[4] - Alibaba and China National Nuclear Corporation formed a joint venture for nuclear energy, potentially benefiting related companies[4] Healthcare Sector - The Hang Seng Healthcare Index rose by 0.7%, with WuXi Biologics increasing by 3.5%[5] - The CXO sector is expected to see a rebound in demand, with a projected 20.6% increase in clinical trial projects per company by 2025[5]